Experience in treating portal thromboses in patients with chronic myeloproliferative diseases


Cite item

Full Text

Abstract

Patients with myeloproliferative diseases (MPD) are noted to be at high risk for portal thromboses. This problem gives rise to disability if it is untimely treated or resistant to therapy. The paper gives the experience of the Outpatient Department of the Hematology Research Center, Ministry of Health of the Russian Federation, in using antithrombin III in MPD patients (3 patients with primary myelofibrosis, 3 with essential thrombocythemia) and acute and subacute portal vein thromboses resistant to therapy with direct anticoagulants. In all 5 cases, the use of antithrombin III in combination with low-molecular-weight heparin showed a positive clinical effect as rapid relief of pain syndrome and comparatively early (3-week to 1.5—2-month) recanalization of thrombosed vessels. Three clinical cases are described in detail.

References

  1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22. doi: 10.1038/sj.leu.2404955.
  2. Skoda R. The genetic basis of myeloproliferative disorders. ASH Education Book. 2007;2007(1):1-10. doi: 10.1182/asheducation-2007.1.1.
  3. Briere JB. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost. 2006;32(3):208-218. doi: 10.1055/s-2006-939432.
  4. Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol. 2000;32:865-871. doi: 10.1016/s0168-8278(00)80259-7.
  5. Janssen HL. Changing perspectives in portal vein thrombosis. Scand JGastroenterol. 2000;232:69-73.
  6. Sobhonslidsuk A, Reddy KR. Portal vein thrombosis: A concise review. Am J Gastroenterol. 2002;97:535-541. doi: 10.1111/j.1572-0241.2002.05527.x.
  7. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22:2020-2028. doi: 10.1038/leu.2008.253.
  8. Marchioli R, Finazzi G, Landolfi R, Landolfi R, Kutti J., Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-2232. doi: 10.1200/jco.2005.07.062.
  9. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-2670. doi: 10.1182/blood-2004-09-3426.
  10. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L, Santini V, Bosi A, Vannucchi AM. Influence of JAK V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008;93(1):41-48. doi: 10.3324/haematol.11653.
  11. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. 2006;108(7):2173-2181. doi:http://dx.doi.org/10.1182/blood-2006-02-005751.
  12. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111(10):4922-4929. doi: 10.1182/blood-2007-11-125328.
  13. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell’Era A, Bucciarelli P, Mannucci PM. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44(6):1528-1534. doi: 10.1002/hep.21435.
  14. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112(2):231-219. doi: 10.1182/blood-2007-12-128454.
  15. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270. doi: 10.1371/journal.pmed.0030270.
  16. Thiele J, Kvasnicka HM. Myelofibrotic transformation in essential thrombocythemia. Haematologica. 2009;94(3):431-433. doi: 10.3324/haematol.2008.001446.
  17. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumors of haematopoietic and lymphoid tissues. Fourth Edition. Lyon: IARC-press; 2008.
  18. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-124. doi: 10.1056/nejmoa035572.
  19. Кузник Б.И. Физиология и патология системы крови. Чита: Полиграф Сервис; 2004.
  20. Abildgaard U. Biological action and clinical significance of antithrombin III. Am J Hematol. 1984;16(1):77-79.
  21. Schatz S, Turecek PL, Fiedler C, Zimmermann K, Gritsch H, Voorberg J, Schwarz HP, Dorner F, Scheiflinger F. Evaluation of the haemostatic potential of factor VIII-heparin cofactor II hybrid proteins in a mouse model. Works-2000. 28 p. Br J Haematol. 2003;123(4):692-895. doi: 10.1046/j.1365-2141.2003.04674.x.
  22. Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis. 2006;17(7):521-526. doi: 10.1097/01.mbc.0000245302.18010.40.
  23. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis. 2002;13(8):657-670. doi: 10.1097/00001721-200212000-00001.
  24. Патент РФ на изобретение №2477636/ 20.03.2013. Бюл. №8. Суханова Г.А., Стоцкая Т.В, Паровичникова Е.Н., Вахрушева М.В., Васильева Е.В., Рудакова В.Е. Способ лечения острых венозных тромбозов различной локализации на фоне геморрагических осложнений. Доступно по: http://www.freepatent.ru/images/patents/433/2477636/patent-2477636.pdf. Ссылка активна на 29.10.2015.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies